D-Cycloserine & iTBS Trial in Fibromyalgia Ends for Futility

Trial Overview and Results

A recent clinical trial investigating the combination of D-Cycloserine with intermittent Theta-Burst Stimulation (iTBS) in treating fibromyalgia was terminated early due to futility. The trial, registered under NCT05395494, aimed to assess whether the adjunctive use of D-Cycloserine could enhance the effects of iTBS on fibromyalgia symptoms. Despite a large overall treatment effect on the Fibromyalgia Impact Questionnaire – Revised (FIQR), no significant difference was observed between the D-Cycloserine and placebo groups, except in depressive symptoms.

Mechanism and Context

Fibromyalgia is a chronic condition characterized by widespread pain and a substantial unmet need for effective treatments. Repetitive Transcranial Magnetic Stimulation (rTMS), and specifically iTBS targeting the dorsolateral prefrontal cortex (DLPFC), has shown potential in reducing symptom severity. D-Cycloserine, a partial agonist of the N-methyl-D-aspartate receptor, has been explored as an adjunct to rTMS in other conditions, hypothesized to enhance neuroplasticity and clinical outcomes.

Implications for Future Research

The trial's findings suggest that iTBS alone may be highly effective in managing fibromyalgia symptoms, potentially overshadowing the adjunctive benefits of D-Cycloserine. This outcome could shift research focus toward optimizing iTBS protocols rather than combining them with pharmacological agents. Future studies may explore different dosages or timing of D-Cycloserine administration to uncover any potential benefits not observed in this trial.

Risks and Unknowns

While the trial demonstrated a significant overall effect of iTBS on fibromyalgia, the specific role of D-Cycloserine remains unclear. The lack of significant difference between the treatment and placebo groups raises questions about the drug's efficacy in this context. Additionally, the trial's early termination limits the understanding of long-term effects and safety of the combined treatment.

Looking Forward

As research continues to seek effective treatments for fibromyalgia, the promising results of iTBS alone warrant further investigation. Researchers may consider exploring other adjunctive therapies or refining iTBS techniques to maximize therapeutic outcomes. The trial's findings underscore the importance of rigorous evaluation in clinical research to ensure the development of safe and effective treatment protocols.